Monomeric IgG in intravenous Ig preparations is a functional antagonist of Fc gamma RII and Fc gamma RIIIb
Monomeric IgG in intravenous Ig preparations is a functional antagonist of Fc gamma RII and Fc gamma RIIIb
Intravenous Ig preparations (IVIg), originally developed as a substitution therapy for patients with low plasma IgG, are nowadays frequently used in the treatment of various immune diseases. However, the mechanism of action of IVIg in these diseases remains elusive and is often referred to as "immunomodulatory." We hypothesized that monomeric IgG may act as a low-affinity FcR antagonist and sought experimental evidence for this hypothesis. Human neutrophils as well FcRIIa-transfected IIA1.6 cells were used as FcR-positive cells and aggregated IgG (aIgG) or stable dimeric IgG as FcR-specific agonists for these cells. We found that monomeric IgG purified from IVIg at concentrations similar to that of IgG in plasma, diminished the binding of stable dimeric IgG to FcRIIa transfectants, reduced aIgG-induced influx of Ca2+ ions into the cytosol of neutrophils, and attenuated the aIgG-induced release of elastase. Notably, monomeric IgG by itself did not elicit these responses, nor did it affect these processes in response to fMLP. Absorption of IgG from normal plasma revealed that plasma IgG exerted similar effects as monomeric IgG in IVIg. In addition, adding monomeric IgG to blood of healthy volunteers showed a dose-dependent decrease of aIgG-induced elastase release. Finally, we observed decreased aIgG-induced polymorphonuclear neutrophil responses in two hypogammaglobulinemic patients upon treatment with IVIg. We conclude that monomeric IgG at physiological levels acts as a low-affinity FcR antagonist. Moreover, FcR antagonism constitutes an immunomodulatory effect of IVIg.
332-339
Mirre, E.
f844cdaf-7642-4fbf-b606-aa8cb985ea64
Teeling, J.L.
fcde1c8e-e5f8-4747-9f3a-6bdb5cd87d0a
Meer, J.W.M.
8b8b52f0-8bc0-4c67-a05d-7392d30a3df8
Meeker, W.K.
2bd64440-803b-44c4-bd96-5826fdabc2ae
Hack, C.E.
30fe6b07-f781-4eba-8476-5b4f509c36f8
1 July 2004
Mirre, E.
f844cdaf-7642-4fbf-b606-aa8cb985ea64
Teeling, J.L.
fcde1c8e-e5f8-4747-9f3a-6bdb5cd87d0a
Meer, J.W.M.
8b8b52f0-8bc0-4c67-a05d-7392d30a3df8
Meeker, W.K.
2bd64440-803b-44c4-bd96-5826fdabc2ae
Hack, C.E.
30fe6b07-f781-4eba-8476-5b4f509c36f8
Mirre, E., Teeling, J.L., Meer, J.W.M., Meeker, W.K. and Hack, C.E.
(2004)
Monomeric IgG in intravenous Ig preparations is a functional antagonist of Fc gamma RII and Fc gamma RIIIb.
Journal of Immunology, 173, .
Abstract
Intravenous Ig preparations (IVIg), originally developed as a substitution therapy for patients with low plasma IgG, are nowadays frequently used in the treatment of various immune diseases. However, the mechanism of action of IVIg in these diseases remains elusive and is often referred to as "immunomodulatory." We hypothesized that monomeric IgG may act as a low-affinity FcR antagonist and sought experimental evidence for this hypothesis. Human neutrophils as well FcRIIa-transfected IIA1.6 cells were used as FcR-positive cells and aggregated IgG (aIgG) or stable dimeric IgG as FcR-specific agonists for these cells. We found that monomeric IgG purified from IVIg at concentrations similar to that of IgG in plasma, diminished the binding of stable dimeric IgG to FcRIIa transfectants, reduced aIgG-induced influx of Ca2+ ions into the cytosol of neutrophils, and attenuated the aIgG-induced release of elastase. Notably, monomeric IgG by itself did not elicit these responses, nor did it affect these processes in response to fMLP. Absorption of IgG from normal plasma revealed that plasma IgG exerted similar effects as monomeric IgG in IVIg. In addition, adding monomeric IgG to blood of healthy volunteers showed a dose-dependent decrease of aIgG-induced elastase release. Finally, we observed decreased aIgG-induced polymorphonuclear neutrophil responses in two hypogammaglobulinemic patients upon treatment with IVIg. We conclude that monomeric IgG at physiological levels acts as a low-affinity FcR antagonist. Moreover, FcR antagonism constitutes an immunomodulatory effect of IVIg.
This record has no associated files available for download.
More information
Published date: 1 July 2004
Identifiers
Local EPrints ID: 56740
URI: http://eprints.soton.ac.uk/id/eprint/56740
ISSN: 0022-1767
PURE UUID: d06c2301-3d79-454f-b507-bb1a453e126e
Catalogue record
Date deposited: 07 Aug 2008
Last modified: 23 Jul 2022 01:53
Export record
Contributors
Author:
E. Mirre
Author:
J.W.M. Meer
Author:
W.K. Meeker
Author:
C.E. Hack
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics